Endoscopic Patient Clustering to Investigate Differential Treatment Effects of Guselkumab and Ustekinumab in Crohn's Disease: Post-hoc Analysis of GALAXI and GRAVITI Trials

Dylan Richards¹, Loqmane Seridi¹, Klebea Sohn¹, Brad Mcrae¹, Nat A. Terry¹, Marion Vetter¹, Daniel Cua¹, Patrick Branigan¹, Walter Reinisch², Raja Atreya³ ¹Janssen Research & Development, LLC, Spring House, PA, USA; ²Division Gastroenterology, Endocrinology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

Background

- Guselkumab (GUS), a selective IL-23p19 subunit inhibitor, demonstrated statistical superiority in endoscopic endpoints to ustekinumab (UST), an IL-23/IL-12p40 subunit inhibitor, by end of maintenance treatment in patients with moderately to severely active Crohn's disease (CD) in the Phase 2/3 GALAXI studies.¹
- Differences in endoscopic response and biological features across ileum- and coloninvolved Crohn's disease (CD) suggest distinct mechanisms for healing.²


Objectives


Understanding endoscopic heterogeneity (i.e., degree of involvement in each segment) across patients may help to delineate treatment effect differences between GUS and UST

Methods

- (525 patients, GALAXI 3).
- assignment of cohort 2.
- between PBO, GUS, and UST.

Results









Key Takeaways



Data-driven endoscopic patient clustering in Crohn's disease can lead to stratified understanding of differential treatment effects between guselkumab (GUS) and ustekinumab (UST)



In addition to overall WK48 endoscopic superiority, endoscopic clustering indicated higher WK12 endoscopic remission with GUS than UST in ~40% of patients


mechanistic research


responders at WK12, and not UST, highlighting potential

Improved narrowing characterized a subset of GUS

role of GUS in affecting stricture biology for future


Improved narrowing at WK12 contributes to endoscopic response with guselkumab, but not with ustekinumab, in patients with stricturing CD






Δ16%

Δ 18%





Endoscopic response (N/Y)